{"url":"https://newsforagent.com/news/2026-11-11/teva-innovative-medicines-revenue-target","markdown_url":"https://newsforagent.com/news/2026-11-11/teva-innovative-medicines-revenue-target.md","title":"Teva Targets $6–7 Billion Innovative Revenue by 2030","headline":"Teva Sets $6–7 Billion Innovative Medicines Goal at First R&D Day","description":"Teva aims for $6–7 billion in innovative medicines revenue by 2030, with one new launch a year and a pipeline of more than $10 billion in peak sales potential.","section":"Research & Clinical Trials","published_at":"2026-11-11T13:01:02+00:00","modified_at":"2026-11-11T13:01:02+00:00","author":"News Desk","key_takeaways":["Teva targets $6–7 billion in innovative medicines revenue by 2030 and one innovative launch per year through 2030.","Teva's late-stage pipeline carries more than $10 billion in combined peak sales potential, subject to regulatory approvals.","Teva returned to an investment grade credit rating in 2026 after generating more than $6 billion in free cash flow from 2023 to 2025."],"companies":[{"name":"Teva Pharmaceuticals","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00008ai/teva-pharmaceuticals","website":"https://www.tevapharm.com"}],"source":{"publisher":"Stock Titan","title":"Teva targets $6-$7B in innovative medicine revenue by 2030","url":"https://www.stocktitan.net/news/TEVA/teva-shares-innovative-pipeline-updates-and-unveils-path-to-future-od6tadbkz0tm.html"},"other_sources":[],"tags":["Research & Clinical Trials","Teva Pharmaceuticals"],"body_markdown":"Teva Pharmaceutical Industries said it aims to reach $6–7 billion in innovative medicines revenue by 2030 and to launch one innovative medicine a year through the end of the decade. The company set out the target at its first R&D Day, [Stock Titan](https://www.stocktitan.net/news/TEVA/teva-shares-innovative-pipeline-updates-and-unveils-path-to-future-od6tadbkz0tm.html) reported on November 11, 2026.\n\n## Inside Teva's First R&D Day\n\n[Teva Pharmaceuticals](https://akta.pro/company-profiles/00008ai/teva-pharmaceuticals) is an Israeli-headquartered, NYSE-listed biopharmaceutical company that develops branded innovative medicines, generics and biosimilars under its Pivot to Growth strategy. President and CEO Richard Francis presented the plan alongside members of the executive leadership and R&D teams.\n\n\"Since then, we have more than doubled our innovative medicines revenue, built a pipeline with more than $10 billion in peak sales potential, and returned to investment grade,\" Francis said of the Pivot to Growth strategy launched in 2023.\n\nTeva said innovative medicines now make up more than 20% of its revenue and that gross margin has improved to approximately 55%. The company counts seven late-stage pipeline assets and ten programs in its innovative pipeline, including two clinical antibodies discovered in-house. Teva also set an innovative gross margin target above 75%, mid-single-digit total revenue growth from 2026 to 2030, a free cash flow target of more than $3.5 billion by 2030 and a path to net debt to adjusted EBITDA of 2.0x by the end of 2027.\n\nOn the pipeline, Teva said its anti-IL-15 Phase 2a study in Celiac disease met its primary endpoint, with a Phase 2b study expected to begin in the second half of 2027. TEV-'408 is advancing into a Phase 2/3 study in vitiligo, and the anti-PD-1/IL-2 asset ATTENUKINE is in Phase 1 development in advanced cancer.\n\n## Teva's Ecopipam Deal and Funding Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Teva closed a $700 million acquisition of Emalex Biosciences in June 2026, adding ecopipam, a first-in-class D1 receptor antagonist for pediatric Tourette syndrome, with up to $200 million in commercial milestones and royalties on top of the upfront payment. The same records show Teva submitted a New Drug Application to the FDA for ecopipam in June 2026, supported by Phase 3 data published in JAMA Neurology, with Orphan Drug and Fast Track designations in place. Teva's funding record includes a $1.7 billion post-IPO debt round in September 2026.\n\n## Teva's Recent Deal and Approval News\n\nOn November 9, 2026, Teva and Samsung Bioepis announced a license and commercialization agreement for two FDA-approved immunology biosimilars, infliximab and etanercept, PMLiVE reported. That same day, Stocktwits noted that the FDA was due to announce a decision on Teva's Igalmi during the week. On October 27, 2026, Teva completed its acquisition of BioXcel Therapeutics assets, including worldwide rights to investigational BXCL501 for at-home treatment of acute agitation in schizophrenia or bipolar disorder, The future of trading reported.\n\n## Teva's Next Pipeline Steps\n\nTeva said the anti-IL-15 Phase 2b study in Celiac disease is expected to begin in the second half of 2027. The company said an archived version of the R&D Day webcast will be posted within 24 hours of the event.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}